CLINICAL_TRIALS
trial_result
· 2016-02-09
Clinical Trial Update: Efficacy and Safety Study of ESBA1008 Versus EYLEA® [Phase 2]
Summary
Phase 2 efficacy and safety trial comparing ESBA1008 to EYLEA in exudative age-related macular degeneration has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alcon Research | Conditions: Exudative Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2016-02-09